Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uroplasty’s Neuromodulator Falls Short On Blue Cross Blue Shield Test

This article was originally published in The Gray Sheet

Executive Summary

Evidence does not support Uroplasty’s Urgent PC neuromodulation system, a 510(k)-cleared device for treating overactive bladder and symptoms, as an effective treatment option, according to an assessment by the Blue Cross Blue Shield’s Technology Evaluation Center.

You may also be interested in...



News Briefs: Lung Screening Recs; Stryker Purchase; CMS News

Federal task force issued final recommendations advising CT screening for people at high risk for lung cancer. Stryker acquired Patient Safety Technologies. CMS announced updates on accountable care organizations. More news briefs.

Uroplasty Ramps Up Incontinence Sales Force As Urgent PC Gains More Coverage

Uroplasty plans to boost its sales force by roughly 50% by the end of November to seize a growing market for its Urgent PC neuromodulation system following a major payer coverage announcement.

Uroplasty Ramps Up Incontinence Sales Force As Urgent PC Gains More Coverage

Uroplasty plans to boost its sales force by roughly 50% by the end of November to seize a growing market for its Urgent PC neuromodulation system following a major payer coverage announcement.

Related Content

UsernamePublicRestriction

Register

MT030077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel